Gerard Socie

Nov 5, 2024 | nature.com | Zahra Mahmoudjafari |Robert Zeiser |Franco Locatelli |Gerard Socie

AbstractREACH2 and REACH3 were randomized, multicenter, open-label phase 3 studies comparing the selective Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib versus investigators’ choice of best available therapy (BAT) in steroid-refractory (SR) acute (REACH2) or chronic (REACH3) graft-versus-host disease (aGVHD/cGVHD).

Apr 7, 2024 | acsjournals.onlinelibrary.wiley.com | Justin Loke |Myriam Labopin |Charles Craddock |Gerard Socie

INTRODUCTION Allogeneic stem cell transplantation (SCT) plays a critical role in the management of acute myeloid leukemia (AML) in reducing the risk of disease relapse through cytotoxicity from the conditioning regimen, as well as through the graft-versus-leukemia (GVL) effect.1-3 To ensure time for this to develop, transplant strategies are premised on allografting patients in complete remission (CR).

Dec 12, 2023 | nature.com | Xavier Poiré |Myriam Labopin |Gerard Socie |Edouard Forcade |Yves Chalandon |Mahmoud Aljurf | +3 more

AbstractAllogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML.

Sep 2, 2023 | nature.com | Arnon Nagler |Nicolaus Kröger |Georg-Nikolaus Franke |Gerard Socie |Johannes Schetelig |Fabio Ciceri

AbstractWe compared outcomes, of 1609 patients with secondary acute myeloid leukemia (sAML) undergoing allogeneic transplantation (HSCT) in first complete remission (CR1) from matched unrelated donors (MUD) from 2010 to 2021, receiving or not receiving anti-thymocyte globulin (ATG) (ATG-1308, no ATG-301). Median age was 60.9 (range, 18.5–77.8) and 61.1 (range, 21.8–75.7) years, (p = 0.3).

Apr 12, 2023 | nature.com | Arnon Nagler |Didier Blaise |Ibrahim Yakoub-Agha |Gerard Socie |Charles Craddock |Fabio Ciceri

AbstractWe compared transplants (HSCT) from matched related siblings (MSD) with those from matched 10/10 and mismatched 9/10 unrelated (UD) and T-replete haploidentical (Haplo) donors in acute myeloid leukemia (AML) in first complete remission (CR1) achieved after two inductions, a known poor prognostic factor. One thousand two hundred and ninety-five patients were included: MSD (n = 428), UD 10/10 (n = 554), UD 9/10 (n = 135), and Haplo (n = 178).